1h Free Analyst Time
Hepatocellular Carcinoma - Pipeline Review, H1 2018Speak directly to the analyst to clarify any post sales queries you may have.
Summary:
This latest Pharmaceutical and Healthcare disease pipeline guide Hepatocellular Carcinoma - Pipeline Review, H1 2018, provides an overview of the Hepatocellular Carcinoma (Oncology) pipeline landscape.
Hepatocellular carcinoma (HCC) is a type of cancer originates from a liver cell (hepatocyte) which becomes cancerous. This type of cancer occurs more often in men than women. Symptoms include abdominal pain or tenderness, especially in the upper-right part, easy bruising or bleeding, enlarged abdomen and yellow skin or eyes (jaundice). The predisposing factors include alcohol abuse, autoimmune diseases of the liver, hepatitis B or C virus infection, inflammation of the liver that is long-term (chronic) and iron overload in the body (hemochromatosis). Treatment includes surgery, chemotherapy and radiation therapy.
Report Highlights:
This latest pipeline guide Hepatocellular Carcinoma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hepatocellular Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hepatocellular Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hepatocellular Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 18, 76, 60, 1, 3, 92, 13 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 10, 6, 1, 1, 25 and 1 molecules, respectively.
Hepatocellular Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatocellular Carcinoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Hepatocellular Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hepatocellular Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hepatocellular Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hepatocellular Carcinoma (Oncology)
Reasons for Purchase:
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hepatocellular Carcinoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hepatocellular Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionHepatocellular Carcinoma - Overview
Hepatocellular Carcinoma - Therapeutics Development
Hepatocellular Carcinoma - Therapeutics Assessment
Hepatocellular Carcinoma - Companies Involved in Therapeutics Development
Hepatocellular Carcinoma - Drug Profiles
Hepatocellular Carcinoma - Dormant Projects
Hepatocellular Carcinoma - Discontinued Products
Hepatocellular Carcinoma - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Hepatocellular Carcinoma, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Hepatocellular Carcinoma - Pipeline by AbbVie Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Abivax SA, H1 2018
Hepatocellular Carcinoma - Pipeline by ACEA Biosciences Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Adaptimmune Therapeutics Plc, H1 2018
Hepatocellular Carcinoma - Pipeline by Advenchen Laboratories LLC, H1 2018
Hepatocellular Carcinoma - Pipeline by Alnylam Pharmaceuticals Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by American Gene Technologies International Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Amgen Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by AndroScience Corp, H1 2018
Hepatocellular Carcinoma - Pipeline by ArQule Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Array BioPharma Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2018
Hepatocellular Carcinoma - Pipeline by AstraZeneca Plc, H1 2018
Hepatocellular Carcinoma - Pipeline by AVEO Pharmaceuticals Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Bavarian Nordic A/S, H1 2018
Hepatocellular Carcinoma - Pipeline by Bayer AG, H1 2018
Hepatocellular Carcinoma - Pipeline by BeiGene Ltd, H1 2018
Hepatocellular Carcinoma - Pipeline by Bio-Cancer Treatment International Ltd, H1 2018
Hepatocellular Carcinoma - Pipeline by Biomics Biotechnologies Co Ltd, H1 2018
Hepatocellular Carcinoma - Pipeline by Bioneer Corp, H1 2018
Hepatocellular Carcinoma - Pipeline by Blueprint Medicines Corp, H1 2018
Hepatocellular Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H1 2018
Hepatocellular Carcinoma - Pipeline by Boston Biomedical Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Bristol-Myers Squibb Co, H1 2018
Hepatocellular Carcinoma - Pipeline by Can-Fite BioPharma Ltd, H1 2018
Hepatocellular Carcinoma - Pipeline by CARsgen Therapeutics Ltd, H1 2018
Hepatocellular Carcinoma - Pipeline by CASI Pharmaceuticals Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by CBT Pharmaceuticals Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by CCRP Therapeutics GmbH, H1 2018
Hepatocellular Carcinoma - Pipeline by Celgene Corp, H1 2018
Hepatocellular Carcinoma - Pipeline by Cellular Biomedicine Group Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Celsion Corp, H1 2018
Hepatocellular Carcinoma - Pipeline by China Medical System Holdings Ltd, H1 2018
Hepatocellular Carcinoma - Pipeline by Chipscreen Biosciences Ltd, H1 2018
Hepatocellular Carcinoma - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018
Hepatocellular Carcinoma - Pipeline by Conatus Pharmaceuticals Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Curevac AG, H1 2018
Hepatocellular Carcinoma - Pipeline by Delcath Systems Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Double Bond Pharmaceutical International AB, H1 2018
Hepatocellular Carcinoma - Pipeline by eFFECTOR Therapeutics Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Eiger BioPharmaceuticals Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Eisai Co Ltd, H1 2018
Hepatocellular Carcinoma - Pipeline by Eli Lilly and Co, H1 2018
Hepatocellular Carcinoma - Pipeline by Epeius Biotechnologies Corp, H1 2018
Hepatocellular Carcinoma - Pipeline by Epizyme Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Eureka Therapeutics Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Exelixis Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Hepatocellular Carcinoma - Pipeline by Faron Pharmaceuticals Oy, H1 2018
Hepatocellular Carcinoma - Pipeline by Galaxy Biotech LLC, H1 2018
Hepatocellular Carcinoma - Pipeline by GC Pharma, H1 2018
Hepatocellular Carcinoma - Pipeline by Genelux Corp, H1 2018
Hepatocellular Carcinoma - Pipeline by Genentech Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Genoscience Pharma, H1 2018
Hepatocellular Carcinoma - Pipeline by Genosco Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Gilead Sciences Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by GlaxoSmithKline Plc, H1 2018
Hepatocellular Carcinoma - Pipeline by Golden Biotechnology Corp, H1 2018
Hepatocellular Carcinoma - Pipeline by H3 Biomedicine Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018
Hepatocellular Carcinoma - Pipeline by Horizon Pharma Plc, H1 2018
Hepatocellular Carcinoma - Pipeline by Immatics Biotechnologies GmbH, H1 2018
Hepatocellular Carcinoma - Pipeline by Immunicum AB, H1 2018
Hepatocellular Carcinoma - Pipeline by Immunitor Inc, H1 2018
Hepatocellular Carcinoma - Pipeline by Immunomedics Inc, H1 2018
List of Figures
Number of Products under Development for Hepatocellular Carcinoma, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Top 10 Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Abivax SA
- ACEA Biosciences Inc
- Adaptimmune Therapeutics Plc
- Advenchen Laboratories LLC
- Alnylam Pharmaceuticals Inc
- American Gene Technologies International Inc
- Amgen Inc
- AndroScience Corp
- ArQule Inc
- Array BioPharma Inc
- Aslan Pharmaceuticals Pte Ltd
- AstraZeneca Plc
- AVEO Pharmaceuticals Inc
- Bavarian Nordic A/S
- Bayer AG
- BeiGene Ltd
- Bio-Cancer Treatment International Ltd
- Biomics Biotechnologies Co Ltd
- Bioneer Corp
- Blueprint Medicines Corp
- Boehringer Ingelheim GmbH
- Boston Biomedical Inc
- Bristol-Myers Squibb Co
- Can-Fite BioPharma Ltd
- CARsgen Therapeutics Ltd
- CASI Pharmaceuticals Inc
- CBT Pharmaceuticals Inc
- CCRP Therapeutics GmbH
- Celgene Corp
- Cellular Biomedicine Group Inc
- Celsion Corp
- China Medical System Holdings Ltd
- Chipscreen Biosciences Ltd
- Chugai Pharmaceutical Co Ltd
- Conatus Pharmaceuticals Inc
- Curevac AG
- Delcath Systems Inc
- Double Bond Pharmaceutical International AB
- eFFECTOR Therapeutics Inc
- Eiger BioPharmaceuticals Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Epeius Biotechnologies Corp
- Epizyme Inc
- Eureka Therapeutics Inc
- Exelixis Inc
- F. Hoffmann-La Roche Ltd
- Faron Pharmaceuticals Oy
- Galaxy Biotech LLC
- GC Pharma
- Genelux Corp
- Genentech Inc
- Genoscience Pharma
- Genosco Inc
- Gilead Sciences Inc
- GlaxoSmithKline Plc
- Golden Biotechnology Corp
- H3 Biomedicine Inc
- Hanmi Pharmaceuticals Co Ltd
- Horizon Pharma Plc
- Immatics Biotechnologies GmbH
- Immunicum AB
- Immunitor Inc
- Immunomedics Inc
- Immunovative Therapies Ltd
- In-Cell-Art SAS
- Incyte Corp
- Inovio Pharmaceuticals Inc
- Inspyr Therapeutics Inc
- InteRNA Technologies BV
- Jiangsu Hengrui Medicine Co Ltd
- Johnson & Johnson
- KAHR medical Ltd
- Karcinolys SAS
- Kite Pharma Inc
- Komipharm International Co Ltd
- Kowa Co Ltd
- Kura Oncology Inc
- Leap Therapeutics Inc
- Lixte Biotechnology Holdings Inc
- MaxCyte Inc
- MedImmune LLC
- Medivir AB
- MELEMA Pharma GmbH
- Merck & Co Inc
- Merck KGaA
- Merrimack Pharmaceuticals Inc
- Midatech Pharma Plc
- Millennium Pharmaceuticals Inc
- Mina Therapeutics Ltd
- Molecular Templates Inc
- MTG Biotherapeutics Inc
- MultiCell Technologies Inc
- NeuroVive Pharmaceutical AB
- Nkarta Inc
- NormOxys Inc
- Novartis AG
- NovaTarg Therapeutics Inc
- Nymox Pharmaceutical Corp
- Omeros Corp
- Oncolys BioPharma Inc
- Oncolytics Biotech Inc
- Oneness Biotech Co Ltd
- Ono Pharmaceutical Co Ltd
- Oxford BioTherapeutics Ltd
- PepVax Inc
- Pfizer Inc
- Pharma Mar SA
- PharmAbcine Inc
- PharmaEssentia Corp
- Phosplatin Therapeutics LLC
- Provecs Medical GmbH
- Provectus Biopharmaceuticals Inc
- Q BioMed Inc
- RedHill Biopharma Ltd
- Regulus Therapeutics Inc
- Rexahn Pharmaceuticals Inc
- Samumed LLC
- Saronic Biotechnology Inc
- Sensei Biotherapeutics Inc
- Shanghai Henlius Biotech Co Ltd
- Shenogen Pharma Group Ltd
- Sillajen Biotherapeutics
- Simcere Pharmaceutical Group
- Spring Bank Pharmaceuticals Inc
- Sun Pharma Advanced Research Company Ltd
- Takeda Pharmaceutical Co Ltd
- TC BioPharm Ltd
- Tessa Therapeutics Pte Ltd
- Therapure Biopharma Inc
- Tiziana Life Sciences Plc
- TRACON Pharmaceuticals Inc
- Trovagene Inc
- Tumorend LLC
- Twoxar Inc
- Tyrogenex Inc
- VasGene Therapeutics Inc
- Verlyx Pharma Inc
- VG Life Sciences Inc
- Vicus Therapeutics LLC
- Xencor Inc
- Xspray Pharma AB
- Yooyoung Pharm Co Ltd
- Zhejiang Conba Pharmaceutical Co Ltd
